Warning  Please take our Crypto Currency survey here
London South East Logo | UK Share Price information

Email Facebook Twitter

Collagen Sol Regulatory News (COS)

Regulatory News for Collagen Sol (COS)

Share Price: 2.80Bid: 2.60Ask: 3.00Change: 0.05 (+1.82%)Riser - Collagen Sol
Spread: 0.40Spread as %: 15.38%Open: 2.75High: 0.00Low: 0.00Yesterday’s Close: 2.75

Trading update and notice of results

Thu, 26th Oct 2017 07:00

RNS Number : 6453U
Collagen Solutions PLC
26 October 2017



Collagen Solutions Plc

(the "Company" or the "Group")


Trading Update and Notice of Results


Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen-based biomaterials for use in research, diagnostics, medical devices, and regenerative medicine, provides an update on trading for the six months to 30 September 2017.


Revenue and other income is expected to be £1.86m, (H1 2016: £1.89m).  Whilst the quality and scale of our sales pipeline are both at their highest levels to date, our first half revenues have been impacted by revenue recognition issues (£150k) and anticipated orders which, for various reasons, have either not materialised or have been delayed by our customers' own internal issues (2016 equivalent £341k). Those revenues affected by revenue recognition will flow through positively during the second-half of the financial year. As already highlighted in our August AGM statement, revenue growth this year is expected to occur in the second-half of the financial year and the Directors believe that the strength and quality of our sales pipeline continues to have the potential to deliver in line with these expectations.


Commenting on outlook, Jamal Rushdy, CEO says: "We remain positive on the long-term prospects of Collagen Solutions and current pipeline of opportunities and new products. During the first half of the financial year, we added eight new early-stage customer deals compared with nine in the entirety of last year. Additionally, a key milestone was met in September when we completed patient assessments in our ongoing eight-year extension clinical study of ChondroMimetic osteochondral scaffold. The resulting data is due to be reported in Q1 2018, followed by a CE mark submission later in 2018, whilst now engaging in partnering discussions. We look forward to providing more detail of progress within the business when we report our Interim results."


The Company will announce its interim results for the six months to 30 September 2017 on Tuesday, 5 December 2017.


About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.




Collagen Solutions Plc

Contact via Walbrook

Jamal Rushdy, Chief Executive Officer  


Gill Black, Chief Financial Officer




Cenkos Securities plc (Nominated Adviser and Broker)

Stephen Keys

Steve Cox   

Tel: 0207 397 8900





Walbrook PR

    Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001






This information is provided by RNS
The company news service from the London Stock Exchange

Related Shares:
Collagen Solutions (COS)

20-Dec-17 11:55RNSChondroMimetic® UpdateCompany Announcement - General
19-Dec-17 15:49RNS-RHardman Research: Targeting long-term growthCompany Announcement - General
18-Dec-17 07:00RNSDirectorate ChangeExecutive Changes
14-Dec-17 07:00RNSAppointment of Chief Financial OfficerExecutive Changes
05-Dec-17 07:00RNSHalf-year ReportResults and Trading Reports
27-Nov-17 16:41RNSSecond Price Monitoring ExtnCompany Announcement - General
27-Nov-17 16:35RNSPrice Monitoring ExtensionCompany Announcement - General
26-Oct-17 07:00RNSTrading update and notice of resultsCompany Announcement - General
21-Sep-17 13:28RNS-RHardman Research: Engineering towards CE MarkCompany Announcement - General
21-Sep-17 07:00RNSStudy Update Patient Assessments CompletedCompany Announcement - General
18-Sep-17 07:00RNS-RPresenting at the Hardman Investor ForumCompany Announcement - General
12-Sep-17 07:00RNSIssue of EquityCompany Announcement - General
30-Aug-17 11:21RNSResult of AGMResults and Trading Reports
30-Aug-17 07:00RNSAGM StatementResults and Trading Reports
26-Jul-17 07:00RNSPosting of Annual Report & notice of AGMCompany Announcement - General
25-Jul-17 11:36RNSDirector/PDMR ShareholdingDirectors' Dealings
25-Jul-17 07:15RNS-RHardman Research: Transition to sustainable growthCompany Announcement - General
13-Jul-17 11:39RNSDirector/PDMR ShareholdingDirectors' Dealings
11-Jul-17 07:00RNSFinal ResultsResults and Trading Reports
07-Jul-17 07:00RNSFirst patient enrolment in ChondroMimetic® studyCompany Announcement - General
19-Jun-17 07:00RNSNotice of ResultsAdvance Notice of Results
13-Jun-17 07:00RNS-RProvisional patent submittedCompany Announcement - General
11-May-17 07:15RNS-RHardman Research: Trading:earnings above forecastsCompany Announcement - General
25-Apr-17 07:00RNSTrading UpdateResults and Trading Reports
24-Apr-17 07:00RNSConsolidation of US R&D activities & Board changeExecutive Changes
10-Apr-17 07:00RNS-RCollagen Based Spray Adhesive Poster PresentedCompany Announcement - General
03-Apr-17 11:22RNSHolding(s) in CompanyHolding(s) in Company
03-Apr-17 07:00RNSAgreement signed with Smart Matrix LimitedCompany Announcement - General
31-Mar-17 16:52RNSHolding(s) in CompanyHolding(s) in Company
29-Mar-17 07:00RNS-RPericardium Divisional Patent in AustraliaCompany Announcement - General

Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.